禮來(LLY.US)14億美元收購癌症藥廠Point Biopharma(PNT.US) 後者盤前飆84%
禮來(LLY.US)周二(3日)表示,將以14億美元收購Point Biopharma Global(PNT.US),以獲得癌症藥實驗療法,交易將於2023年底完成。
收購價每股12.5美元較Point Biopharma周一收市價飆87%,Point Biopharma周二開市前交易股價飆升84%。
Point Biopharma目前正為測試候選放射性配體療法PNT2002和PNT2003的後期研究,實驗療法將殺死細胞的放射性粒子與附著在腫瘤上的分子結合。
Point Biopharma與Lantheus Holdings(LNTH.US)共同開發的PNT2002,預計將與諾華(NOVN.US)的前列腺癌放射配體療法Pluvicto競爭,後者自2022年起在美國上市。Point Biopharma亦擁有針對一種極其罕見的消化道癌症的實驗候選藥物PNT2003。
禮來更將獲得Point Biopharma位於美國印城的放射性藥物製造工廠,以及位於加拿大多倫多的研發中心的使用權。
禮來一直透過小額收購以加強其產品線,因為其癌症治療藥物Alimta面臨仿製藥的激烈競爭,同時押注重磅藥物Mounjaro。禮來今年以24億美元收購Dice Therapeutics和以19.3億美元收購私人控股的Versanis。
(me/m)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.